Enrollment Resumes in Masitinib Trials at Some European Sites
A French national agency has cleared AB Science to resume patient enrollment in the Phase 3 clinical trial investigating…
Articles by Patricia Inácio, PhD
ProMIS to Validate TDP-43 Antibodies for ALS Treatment
ProMIS Neurosciences is advancing the development of antibodies against toxic TDP-43 protein clumps for the treatment of amyotrophic lateral…
NIH Grants $10M to US Trial of Stentrode Brain Implant for Paralysis
A $10-million grant from the National Institutes of Health (NIH) will help fund the first U.S.-based clinical trial of…
Companies Focus on ALS in Partnering AI, Drug Discovery Skills
Bringing artificial intelligence (AI) to the development of small molecule therapies for amyotrophic lateral sclerosis (ALS) and other neurological…
Ketamine Earns FDA’s Orphan Drug Designation
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ketamine, PharmaTher’s investigational therapy for…
Enrollment Open for COURAGE-ALS Trial of Reldesemtiv
Patient enrollment has begun for Cytokinetics‘ pivotal Phase 3 clinical trial investigating reldesemtiv for the treatment of people…
FDA Grants Orphan Drug Status to Coya’s T-cell Therapy ALS001
Coya Therapeutics’ ALS001, a potential regulatory T-cell (Treg) therapy designed to halt amyotrophic lateral sclerosis (ALS) progression, has…
Alector, GSK Team Up to Develop 2 Antibody Treatments for ALS
Alector and GlaxoSmithKline (GSK) have established a partnership to develop two investigational antibodies — called AL001 and AL101…
Clene Readying for HEALEY Trial Results of CNM-Au8 in Slowing ALS
Clene and its subsidiary Clene Nanomedicine are negotiating to increase their manufacturing capacity as they prepare to release findings —…
Investigational RNA Molecule May Slow ALS Progression
An investigational RNA molecule called an RNA aptamer halted the death of motor neurons and helped preserve motor function in…